Bioresponsive engineered nanoparticles for immunomodulation

Nanomaterials possess significant immunomodulatory capabilities, enhancing both disease prevention and therapeutic efficacy in vivo, yet their clinical translation is hindered by complex fabrication methods and high production costs. Future efforts must focus on simplifying synthesis and improving cost-efficiency to facilitate their adoption in clinical practice.